Abstract:Due to the restrictions of liver transplantation, complication-guided pharmacological therapy has become the mainstay of long-term management of cirrhosis. This article aims to provide a complete overview of pharmacotherapy options that may be commenced in the outpatient setting which are available for managing cirrhosis and its complications, together with discussion of current controversies and potential future directions. PubMed/Medline/Cochrane Library were electronically searched up to December 2018 to identify studies evaluating safety, efficacy and therapeutic mechanisms of pharmacological agents in cirrhotic adults and animal models of cirrhosis. Non-selective beta-blockers effectively reduce variceal re-bleeding risk in cirrhotic patients with moderate/large varices, but appear ineffective for primary prevention of variceal development and may compromise renal function and haemodynamic stability in advanced decompensation. Recent observational studies suggest protective, haemodynamically-independent effects of beta-blockers relating to reduced bacterial translocation. The gut-selective antibiotic rifaximin is effective for secondary prophylaxis of hepatic encephalopathy; recent small trials also indicate its potential superiority to norfloxacin for secondary prevention of spontaneous bacterial peritonitis. Diuretics remain the mainstay of uncomplicated ascites treatment, and early trials suggest alpha-adrenergic receptor agonists may improve diuretic response in refractory ascites. Vaptans have not demonstrated clinical effectiveness in treating refractory ascites and may cause detrimental complications. Despite initial hepatotoxicity concerns, safety of statin administration has been demonstrated in compensated cirrhosis. Furthermore, statins are suggested to have protective effects upon fibrosis progression, decompensation and mortality. Evidence as to whether proton pump inhibitors cause gut-liver-brain axis dysfunction is conflicting. Emerging evidence indicates that anticoagulation therapy reduces incidence and increases recanalisation rates of non-malignant portal vein thrombosis, and may impede hepatic fibrogenesis and decompensation. Pharmacotherapy for cirrhosis should be implemented in accordance with up-to-date guidelines and in conjunction with aetiology management, nutritional optimisation and patient education.

Emerging synthetic drugs for the treatment of hepatic cirrhosis: a 2024 update

Emerging synthetic drugs for the treatment of liver cirrhosis

Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment

Drug treatments to prevent first decompensation in cirrhosis

Emerging Therapies for Liver Fibrosis

Emerging Pharmacotherapies in Alcohol-Associated Hepatitis

Innovative prophylactic and therapeutic approaches in liver cirrhosis

Emerging Pharmacologic Treatments for Alcohol-Associated Hepatitis: Current Status and Future Landscape

Current and future pharmacological therapies for managing cirrhosis and its complications

The Burden of Liver Cirrhosis and Underlying Etiologies: Results from the Global Burden of Disease Study 2019

Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis

Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents

Current and Emerging Approaches for Hepatic Fibrosis Treatment

Global epidemiology of cirrhosis — aetiology, trends and predictions

Epidemiology of liver diseases: global disease burden and forecasted research trends

Managing cirrhosis with limited resources: perspectives from sub-Saharan Africa

Prescription rates of common medications in patients with decompensated cirrhosis in Germany

The burden of liver cirrhosis in mortality: Results from the global burden of disease study

An update on the recent advances in antifibrotic therapy

Alcoholic liver fibrosis: detection and treatment

Current and future treatment for alcoholic‐related liver diseases